Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TGF-beta 3

TGF-beta 3

Brief Information

Name:Transforming growth factor beta 3
Target Synonym:Transforming Growth Factor beta3,TGFB3,LAP,Prepro-Transforming Growth Factor Beta-3,TGF-Beta3,Transforming Growth Factor, Beta 3,ARVD1,LDS5,Arrhythmogenic Right Ventricular Dysplasia 1,RNHF,Transforming growth factor beta-3 proprotein,ARVD
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

TG3-H5213-Cell-based assay
 TGF-beta 3 CELL

Human TGF-beta 3, premium grade (Cat. No. TG3-H5213) inhibits the Human IL-4, premium grade (Cat. No. IL4-H4218) dependent proliferation of TF-1 cells. The EC50 for this effect is 0.0166 ng/mL (Routinely tested).

 TGF-beta 3 ELISA

Immobilized Human TGFBR2, Fc Tag (Cat. No. TG2-H5252) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Latent TGFB3, His,Avitag (Cat. No. TG3-H82E6) with a linear range of 0.3-20 ng/mL (QC tested).

 TGF-beta 3 ELISA

Immobilized Human Latent TGF-beta 3, His Tag (Cat. No. TG3-H52H5) at 2 μg/mL (100 μL/well) can bind Biotinylated Human TGFBR2, Fc,Avitag (Cat. No. TG2-H82F6) with a linear range of 0.2-2 ng/mL (QC tested).

Synonym Name



Transforming growth factor beta 3 ( TGFB3) is also known as TGF-β3, is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including regulates embryogenesis and cell differentiation and is required in various processes such as secondary palate development.  TGF-beta 3 is similar with TGF-beta 1 and ­-beta 2, act as cellular switches to regulate immune function, cell proliferation, and epithelial­-mesenchymal transition.  TGF-beta-3 is released from LAP by integrins: integrin-binding results in distortion of the LAP chain and subsequent release of the active TGF-beta-3. Once activated following release of LAP, TGF-beta-3 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Dalutrafusp alfa GS-1423; AGEN-1423 Phase 2 Clinical Agenus Inc Liver Neoplasms; Solid tumours; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal Details
RG-6315 RG-6315 Phase 1 Clinical Genentech Inc Scleroderma, Systemic Details
AVID-200 AVID-200; BMS-986416; AVID-200 DP Phase 1 Clinical Formation Biologics Corp Solid tumours; Polycythemia Vera; Primary Myelofibrosis; Scleroderma, Diffuse; Thrombocythemia, Essential Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message